透過您的圖書館登入
IP:3.144.202.167
  • 期刊

Recent Advances in Therapy for Gastric Cancer

胃癌治療學之最新進展

並列摘要


Gastric cancer is the fourth leading cause of death from cancer in Taiwan. Complete surgical resection is the only potentially curative treatment for gastric cancer. Randomized trials have failed to show the superiority of D2 over D1 dissection, and comparisons showing higher survival rates following more extensive surgery in Japan may have been influenced at least in part by the fact that D1 dissection underestimates disease stage in Western populations. No studies have shown convincing evidence of a survival benefit from adjuvant chemotherapy. A regimen of postoperative 5-fluorouracil (5-FU)-based chemoradiotherapy can improve disease-free and overall survival compared with surgery alone. Inadequate lymph node dissection for local control is a major concern. For advanced disease, HDFL (weekly 24-hour infusion of high-dose 5-FU and leucovorin)-based ‘doublet’ chemotherapy forms a cornerstone of combination chemotherapy in gastric cancer, but the effect on prolonged median survival is minimal. A ‘sequential’ non-cross-resistant strategy may be useful to prolong overall survival in patients with advanced gastric cancer. There are indications that preoperative neoadjuvant chemotherapy or chemoradiotherapy may increase the resectability of tumors and reduce the risk of postoperative recurrence. In the future, substantial improvements of treatment outcome will likely depend on the integration of novel, molecularly targeted agents into multimodality treatment strategies for all stages of gastric cancer. Further clinical research is mandatory to develop optimal therapies for gastric cancer.

並列關鍵字

Chemotherapy Gastric cancer Radiotherapy Review Surgery

被引用紀錄


Tuan, T. F. (2013). 利用太平洋紫杉醇治療胃癌轉移與胃癌轉移相關基因之研究 [doctoral dissertation, Taipei Medical University]. Airiti Library. https://doi.org/10.6831/TMU.2013.00050
游璧如(2005)。臺灣原生種植物之抗癌活性研究〔碩士論文,臺北醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0007-1704200714554168
劉威辰(2006)。臺灣地區癌症病患使用醫療費用及其財務保障之探討〔碩士論文,亞洲大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0118-0807200916273935

延伸閱讀


  • 賴峻毅、陳明晃(2020)。免疫治療在轉移性胃癌之新進展臨床醫學月刊85(2),92-95。https://doi.org/10.6666/ClinMed.202002_85(2).0016
  • 蘇銘堯(2015)。胃腸道惡性腫瘤診治新進展內科學誌26(3),150-155。https://doi.org/10.6314/JIMT.2015.26(3).04
  • 黃家偉(2015)。胃癌治療新趨勢台北市醫師公會會刊59(7),43-48。https://www.airitilibrary.com/Article/Detail?DocID=P20110322001-201507-201508110013-201508110013-43-48
  • 姚鍾太、周繡玲(2009)。胃癌治療的新趨勢腫瘤護理雜誌9(S),37-50。https://doi.org/10.6880/TJON.200912/SP_9.04
  • 葉坤輝(1998)。胃癌化學治療之進展當代醫學(298),624-626。https://doi.org/10.29941/MT.199808.0006